▼ Summary
– The FDA refused to review Moderna’s application for its mRNA flu vaccine, citing issues with the trial’s comparator vaccine design.
– Moderna was surprised by the refusal, noting the FDA had previously reviewed and accepted the trial design on multiple occasions.
– The company’s large Phase 3 trial found its mRNA flu vaccine was superior to the licensed standard-dose vaccines it was compared against.
– The article frames this decision as part of broader hostility toward vaccines under FDA leadership appointed by anti-vaccine activist Robert F. Kennedy Jr.
– Under this leadership, the FDA has already reduced childhood vaccine recommendations and canceled significant mRNA research funding.
The Food and Drug Administration has declined to accept Moderna’s application for its mRNA-based influenza vaccine, a significant setback for the company’s efforts to expand its messenger RNA technology beyond COVID-19. This unexpected regulatory decision centers on the agency’s stated concerns regarding the design of the pivotal clinical study, despite Moderna’s assertion that its trial protocol had received prior feedback.
In a recent announcement, Moderna expressed surprise at the FDA’s refusal to file the application for its vaccine candidate, mRNA-1010. The agency specifically questioned the comparator vaccine used in the large-scale Phase 3 trial. That study, which involved close to 41,000 participants and represented a major financial investment, demonstrated that Moderna’s mRNA flu vaccine was more effective than the existing licensed vaccines it was tested against, which included GlaxoSmithKline’s Fluarix.
The company contends that the FDA had reviewed and accepted the trial design on multiple occasions before the formal application was submitted. Moderna also pointed out that the comparator vaccine in question has been utilized in previous successful influenza vaccine trials that ultimately led to product approvals. This development occurs within a broader context of shifting federal health priorities, which have included revised childhood immunization schedules and redirected research funding, contributing to an atmosphere of uncertainty for vaccine developers.
(Source: Ars Technica)
